2 new development(s) in neoantigen vaccines today.
Merck & Co., Inc. (NYSE:MRK) shares rose as positive trial results for the personalized cancer vaccine intismeran autogene—developed with Moderna—revived investor interest, while MRK’s 13% stake in Personalis and support for Tempus AI’s $1.5B sale at $16.25 tie strategic sequenci…
Moderna is leveraging the Phase 3 success of its personalized mRNA cancer vaccine to expand its pipeline into universal cancer vaccines and in-body immune cell modification technologies. A common-antigen targeted therapy requiring no patient-specific manufacturing process, along …
neoag.ai tracks clinical, commercial, and AI-methods movement across personalized cancer vaccines, trial activity, TCR/pMHC tools, and market catalysts. Sources are linked inline, synthesized locally, and organized for biotech, investor, and research readers.